Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
82 hedge funds and large institutions have $448M invested in Epizyme, Inc in 2014 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 25 closing their positions.
1,239% more call options, than puts
Call options by funds: $241K | Put options by funds: $18K
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less funds holding
Funds holding: 94 → 82 (-12)
30% less capital invested
Capital invested by funds: $639M → $448M (-$191M)
36% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$62.9M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$7.74M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$5.28M |
| 4 |
Millennium Management
New York
|
+$4.34M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$15.9M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$15.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$12.2M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$10.4M |
| 5 |
JP Morgan Chase
New York
|
-$10.4M |
EPZM Hedge Fund Activity: Q4 2014 in Review
82 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2014, worth a combined $448M — down 30% from $639M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of EPZM and 16 opened new positions — a net loss of 9 holders — while 25 trimmed existing stakes and 26 added.
The largest buyer was Primecap Management, adding an estimated $62.9M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $15.9M sold.
- 82 institutional investors held Epizyme, Inc (EPZM) as of Q4 2014, down from 94 in Q3 2014.
- Funds reported $448M of Epizyme, Inc stock for Q4 2014, down 30% quarter-over-quarter.
- 16 funds opened new Epizyme, Inc positions in Q4 2014 and 25 closed out, a net change of -9 holders.
- The largest Epizyme, Inc buyer in Q4 2014 was Primecap Management, an estimated $62.9M added.
- The largest Epizyme, Inc seller in Q4 2014 was T. Rowe Price Associates, an estimated $15.9M sold.
Based on aggregated 13F filings for Q4 2014.